RAB8A, RAB8A, member RAS oncogene family, 4218
N. diseases: 69; N. variants: 3
Source: ALL
| Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.060 | Biomarker | group | BEFREE | One of these compounds, <b>BRD9500</b>, was active in an SK-MEL-3 xenograft model of cancer. | 31749907 | 2019 | ||||
|
0.060 | Biomarker | group | BEFREE | These results have important implications for the development of new therapeutic targets, Klotho-related research in the context of NSCLC as well as other areas, and provide a working model for Rab8 function in the context of cancer and cancer biology. | 31707148 | 2019 | ||||
|
0.060 | Biomarker | group | BEFREE | More detailed investigation in concentration-dependent mode against normal (ARPE-19) and two cancer cell lines (PANC-1 and SK-MEL-2) identified two lead compounds one of which displayed a notable cytotoxicity toward pancreatic cancer cells while the other targeted the melanoma cells. | 30826507 | 2019 | ||||
|
0.060 | AlteredExpression | group | BEFREE | The synthesized compounds 6(a-j) were appraised for their in vitro anticancer activity against human cancer cell lines such as SK-MEL-2 (melanoma), IMR-32 (Neuroblastoma), HT-29(Colon) and also on normal murine embryonic fibroblast NIH/3T3 by Sulforhodamine B (SRB) assay, using Adriamycin as a standard drug. | 29667556 | 2018 | ||||
|
0.060 | Biomarker | group | BEFREE | The cancer cell lines used in this research work are SK-MEL-2 (melanoma), MCF-7 (breast cancer), IMR-32 (neuroblastoma) MG-63 (human osteosarcoma), HT-29 (human colon cancer) and Hep-G2 (human hepatoma). | 30096835 | 2018 | ||||
|
0.060 | Biomarker | group | BEFREE | A dose-dependent decrease in cell viability was observed for the tumoral cell lines, A431 and SK-MEL-5, with a significant reduction of the A431 cancer cell line viability. | 29684903 | 2018 |